click enter text
invest summari yesterday morn provid updat
guidanc provid outlook fourth quarter adj
oper profit growth adj ep move low-end prior
rang earn growth fairli mute albeit due
part suspens share repurchas program embark
somewhat unchart path remak well consum
health experi merg aetna plu side manag
team proven time incred capabl valuat
remain well-below long-term histor averag offset posit
potenti loss healthcar plan caremark pbm
potenti entranc amazon industri balanc factor
remain peer perform rate equiti
outlook adj ep estim move
respect
gener reduc oper profit pharmaci servic oper
off-set benefit lower tax rate forecast
exclud increment debt cost associ acquisit aetna
page detail underli forecast pro forma
earn analysi model reflect acquisit aetna
valuat trade ntm consensu ep well-below
long-term histor averag calendar year-end fair valu
estim low repres approx pro forma
adj ep reflect acquisit aetna valuat
well-below long-term averag believ risk profil around
increas driven subdu growth stand-alone compani
uncertainti around potenti growth profil merg compani
note ep estim pro forma announc acquisit aetna
trade fundament data
price et
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
outperform broader market far far calendar year
et today ahead rise calendar year equiti fell
compar rise calendar fell vs rise
 trade ntm consensu ep compani
averag respect ev/ebitda basi trade in-
line averag averag respect
base fair valu estim share pro forma earn estim
reflect compani announc acquisit aetna calendar year-end fair valu estim
low repres approxim discount current price-to-earnings multipl pro forma adj
ep compar prior fair valu estim share base stand-
alon basi prior calendar year-end fair valu estim near repres approxim
adj ep estim continu believ use price-to-earnings multipl discount
compani price-to-earnings averag appropri given number factor includ slow-down growth
potenti amazon enter pharmaceut dispens market believ ultim occur
potenti attrit exist pbm busi light merger aetna uncertainti
around cvs/aet consum health experi entail growth profil
combin busi time previous also reli dcf analysi reflect
intrins valu stand-alone basi given announc merger aetna place
emphasi pro forma earn analysi valu share better pictur emerg long-
term cash flow potenti pro forma merg compani
risk peer perform rate
risk upsid
equiti valuat histor averag inde equiti trade well-below
long-term histor averag coupl dcf valuat stand-alone basi suggest
intrins valu well-abov equiti price posit news potenti translat higher equiti
price
win larg pbm contract similar downsid risk present loss larg pbm client
flipsid situat win larg pbm client could lead higher sale earn equiti price
strong manag team focus return organ stronger
growth team proven mani year strong steward busi
increasingli challeng landscap also return signific capit sharehold time
busi see challeng rebuild period sort believ team work
hard re-acceler growth compani abl sooner stronger fashion could lead
sale earn upsid rel current forecast potenti higher equiti price
page
produc signific cash flow focus enhanc sharehold return
multi-year period produc signific oper free cash flow help enterpris fund
grow dividend sizabl share repurchas annual believ compani oper model like
continu allow manag team return larg amount capit sharehold year
continu focus sharehold return next year like aberr return
capit sharehold due aetna acquisit suspens share repurchas program
lower leverag achiev howev busi perform expect would anticip
compani return capit sharehold may current anticip
announc acquisit aetna lead stronger growth profit combin basi
merger lead increas top-line growth less-than-anticip pbm client friction well stronger
profit part higher synergi could lead stronger earn higher valuat
thu higher equiti price time
risk downsid
growth profit outlook pro forma /aet enterpris lower-than-anticip
stand-alone compani also experienc subdu oper perform late particularli
pbm oper time embark path remak consum health experi
conjunct announc acquisit aetna remak experi take longer-than-anticip
could lead lower revenu earn growth synergi combin organ
lower-than-anticip need reinvest meaning busi could also
pressur oper result final pbm see more-than-anticip attrit client base and/or
amazon enter industri scenario would like hurt result
diminish compani vertic model advantag last year competitor teamed-
offer similar program offer like mainten choic part result lose
script retail pharmaci segment reaction allow retail platform bring pbm
healthcar plan certain program exclus caremark pbm competitor continu
success mimic vertic model and/or decis let retail pharmaci busi partner
compani result signific loss caremark competit stand could detriment
revenu growth profit time major pbm oper particularli
script attempt carv retail pharmaci network could quit detriment earn
increas government involv healthcar industri long-term believ
encroach govern healthcar industri remain largest risk ultim form
govern control would government-sponsor system idea float time time
certain constitu washington appear countri move toward single-payor
system even slowli direct public option could weigh valuat
need mani servic could wane time scenario would note
manag strongli believ much outlier event
page
amazon enter prescript drug dispens market believ amazon enter market
next year like partnership larg pbm like express script inde
case believ entranc amazon industri would neg impact retail
oper pbm busi caremark time believ amazon would infrastructur
fulfil recur acut script technolog interfac mimic mani store
program seem potenti expos issu concern broader retail
pharmaci industri doesnt happen take longer-than-than anticip occur would like
posit equiti
market share volum gain particularli health plan client materi
chang healthcar landscap health care plan play larger role marketplac
lower enterpris share health plan client rel employ client unabl increas
share script volum processed/dispens own asset health plan client could lead
subdu growth compani come year
enterpris profit growth less-than-anticip combin reimburs pressur busi
mix less increment benefit sourc gener like place pressur compani profit
margin near/medium-term vertic model time help mitig variou industri
headwind headwind becom greater-than-anticip profit could lower-than-expect
industri becom competit consum retail landscap pbm industri
remain competit action industri particip drive increas traffic retail drugstor
greater promot exampl attempt captur addit pbm client util price-driven strategi
could impact sale profit addit believ like entranc amazon
industri would real threat well broader retail pharmaci industri
increas reimburs pressur lower reimburs rate continu place downward
pressur profit margin reimburs pressur increas current anticip
could place even pressur profit increas govern involv long-
term could exacerb margin pressur govern program account approxim
reimburs govern predisposit put pressur profit healthcar industri
broadli could see acceler deterior reimburs rate time
unexpect loss larg pbm contract health pbm busi maintain high client
retent rate howev unexpect loss larg pbm client would like pressur sale profit
compani
page
earn driver outlook
revis ep estim move low-end compani prior
guidanc slightli reduc overal growth enterpris driven lower
growth pharmaci servic segment retail/ltc segment continu estim slightli
neg store sale quarter relat profit reduc oper
profit margin expans pharmaci servic segment drive bulk reduc forecast
quarter retail side see slightli contract oper margin y/i moder
contract oper margin previous given suspens share repurchas program due
announc acquisit aetna also elimin previous small amount
estim share repurchas activ quarter ep estim lead adj ep
rais ep outlook driven larg benefit tax reform
reduc oper profit outlook underli busi forecast
consolid net revenu growth approx approx previous see oper profit
growth approxim roughli prior forecast top-line slightli rais
forecast retail/ltc segment reduc revenu growth pbm retail segment
continu see modest oper margin compress slightli prior forecast lead low
singl digit oper profit growth pharmaci servic busi combin lower top-line
growth slightli less oper margin expans prior forecast lead oper profit growth
approx roughli previous given announc transact aetna elimin
share repurchas activ fiscal year previous forecast billion prior
stand-alon forecast offset reduc oper profit outlook headwind ep
suspens share repurchas activ much lower estim tax rate compar
prior estim part outlook updat yesterday compani outlin interest
expens billion includ approx billion interest expens exist portfolio
would leav approxim billion relat deal bridg financ outlin
compani note bridg financ fee would exclud adj
ep adj ep forecast also exclud interest expens relat debt aetna transact
given compani isnt receiv offset revenue/incom aetna exact close date
remain fluid pleas see pro forma /aet analysi model better reflect
potenti pro forma earn includ transaction-rel adjust impact relat merg
ep estim move reduc revenu growth outlook
enterpris predominantli pbm also retail busi well estim overal top-line
growth approxim approx also reduc profit enterpris
pbm retail side busi given potenti continu busi headwind well
reinvest busi drive long-term growth given time aetna transact
move part forecast stand-alone busi fulli reflect combin aetna
continu forecast interest expens exclud cost relat fund aetna
transact resum share repurchas activ incorpor lower tax rate
forecast pleas see pro forma /aet analysi model better reflect
potenti pro forma earn includ transaction-rel adjust impact relat merg
page
accord pro forma analysi combin aetna estim
adj ep forecast reflect combin revenu billion ebitda billion
forecast take account potenti synergi combin addit debt share
issu fund transact associ higher interest expens suspens share
repurchas activ lower leverag level met benefit tax legisl among factor
pleas see model detail pro forma earn analysi
page
earn outlook tabl segment retail pharmaci consolid pharmaci consolid gross interseg segment total ebit consolid retail pharmaci consolid pharmaci interest expens interseg consolid gross incom net incom attribut ex retail pharmaci adj net incom cont op attribut ex pharmaci segment dilut ep attribut ex adj ep cont op attribut ex retail pharmaci pharmaci gener corpor weight average dilut share interseg ebit growth rate consolid gross retail pharmaci store ebit adj net incom cont op attribut ex adj ep cont op attribut ex pharmaci claim processedmail margin consolid retail pharmaci gross sg ebit average revenu mail retail pharmaci chang marginavg revenu gross sg ebit tax
